Alzheimer's Disease

Alzheimer's disease (AD) is the most common form of dementia (a brain disorder that seriously affects a person's ability to carry out daily activities) among older people. It involves the parts of the brain that control thought, memory, and language. Every day scientists learn more, but right now the causes of Alzheimer's disease are still unknown, and there is no cure.

Alzheimer's disease is named after Dr. Alois Alzheimer, a German doctor. In 1906, Dr. Alzheimer noticed changes in the brain tissue of a woman who had died of an unusual mental illness. He found abnormal clumps (now called amyloid plaques) and tangled bundles of fibers (now called neurofibrillary tangles). Today, these plaques and tangles in the brain are considered hallmarks of Alzheimer's disease.

Scientists also have found other brain changes in people with Alzheimer's disease. There is a loss of nerve cells in areas of the brain that are vital to memory and other mental abilities. There also are lower levels of chemicals in the brain that carry complex messages back and forth between nerve cells. Alzheimer's disease may disrupt normal thinking and memory by blocking these messages between nerve cells.

Scientists do not yet fully understand what causes Alzheimer's disease. There probably is not one single cause, but several factors that affect each person differently. Age is the most important known risk factor for Alzheimer's disease. The number of people with the disease doubles every 5 years beyond age 65.

Family history is another risk factor. Scientists believe that genetics may play a role in many Alzheimer's disease cases. For example, familial Alzheimer's disease, a rare form of Alzheimer's disease that usually occurs between the ages of 30 and 60, can be inherited. However, in the more common form of Alzheimer's disease, which occurs later in life, no obvious family pattern is seen. One risk factor for this type of Alzheimer's disease is a protein called apolipoprotein E (apoE).

Everyone has apoE, which helps carry cholesterol in the blood. The apoE gene has three forms. One seems to protect a person from Alzheimer's disease, and another seems to make a person more likely to develop the disease. Other genes that increase the risk of Alzheimer's disease or that protect against Alzheimer's disease probably remain to be discovered.

Scientists still need to learn a lot more about what causes Alzheimer's disease. In addition to genetics and apoE, they are studying education, diet, environment, and viruses to learn what role they might play in the development of this disease.

Alzheimer's disease begins slowly. At first, the only symptom may be mild forgetfulness. People with Alzheimer's disease may have trouble remembering recent events, activities, or the names of familiar people or things. Simple math problems may become hard to solve. Such difficulties may be a bother, but usually they are not serious enough to cause alarm.

However, as the disease goes on, symptoms are more easily noticed and become serious enough to cause people with Alzheimer's disease or their family members to seek medical help. For example, people in the later stages of Alzheimer's disease may forget how to do simple tasks, like brushing their teeth or combing their hair. They can no longer think clearly. They begin to have problems speaking, understanding, reading, or writing. Later on, people with Alzheimer's disease may become anxious or aggressive, or wander away from home. Eventually, patients need total care.

No treatment can stop Alzheimer's disease. However, for some people in the early and middle stages of the disease, the drugs tacrine (Cognex), donepezil (Aricept), rivastigmine (Exelon), or galantamine (Razadyne® (formerly known as Reminyl®)) may help prevent some symptoms from becoming worse for a limited time. Also, some medicines may help control behavioral symptoms of Alzheimer's disease such as sleeplessness, agitation, wandering, anxiety, and depression. Treating these symptoms often makes patients more comfortable and makes their care easier for caregivers.

The fifth approved medication, known as Namenda® (memantine), is an N-methyl D-aspartate (NMDA) antagonist. It is prescribed for the treatment of moderate to severe Alzheimer's disease. Studies have shown that the main effect of Namenda® is to delay progression of some of the symptoms of moderate to severe Alzheimer's disease. The medication may allow patients to maintain certain daily functions a little longer. For example, Namenda® may help a patient in the later stages of Alzheimer's disease maintain his or her ability to go to the bathroom independently for several more months, a benefit for both patients and caregivers.

ADEAR - Alzheimer's Disease Education & Referral Center